Regeneron Pharmaceuticals, Inc.
NASDAQ: REGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer
- Employees
- 15,158
- Headquarters
- Tarrytown, United States
- IPO year
- 1991
- Market cap
- $62.8B
- Website
- https://www.regeneron.com
Loading REGN…
Loading profile data…Frequently asked questions about REGN
What does Regeneron Pharmaceuticals, Inc. (REGN) do?
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degenera...
Where does REGN trade?
Regeneron Pharmaceuticals, Inc. (REGN) trades on the NASDAQ Global Select.
What sector is REGN in?
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Regeneron Pharmaceuticals, Inc.?
Leonard S. Schleifer is the chief executive officer of Regeneron Pharmaceuticals, Inc. (REGN).
Where is Regeneron Pharmaceuticals, Inc. headquartered?
Regeneron Pharmaceuticals, Inc. is headquartered in United States.
Does REGN pay a dividend?
Yes — Regeneron Pharmaceuticals, Inc. (REGN) paid a trailing twelve-month dividend of USD 3.76 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did REGN go public?
Regeneron Pharmaceuticals, Inc. (REGN) completed its initial public offering in 1991.